Related Experiment Video
Updated: Jun 5, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Successful eravacycline monotherapy for cefiderocol-resistant Acinetobacter baumannii bloodstream infection in a
Luca Pipitò1, Antonio Anastasia2, Giulio D'Agati1
1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ``G D'Alessandro'', University of Palermo, Palermo, Italy; Infectious and Tropical Disease Unit, AOU Policlinico ``P. Giaccone'', Palermo, Italy.
Abstract:
Carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections (BSIs) are associated with high mortality and limited therapeutic options, particularly when resistance to novel agents such as cefiderocol emerges. We report the case of an 87-year-old critically ill woman with multiple comorbidities who developed cefiderocol-resistant CRAB BSI during hospitalization, concomitant with Clostridioides difficile colitis. The patient had previously received broad-spectrum antimicrobial therapy and ventilatory support. Cefiderocol resistance was detected by gradient diffusion (MIC Test Strip) on iron-depleted Mueller-Hinton agar, showing an MIC of 12 mg/L. Considering the resistance profile and concurrent C. difficile infection, antimicrobial therapy was switched to eravacycline monotherapy (1 mg/kg every 12 hours). Eravacycline susceptibility testing by gradient diffusion (ETEST) demonstrated an MIC of 0.75 mg/L. Treatment was administered for 14 days, resulting in clinical improvement and blood culture sterilization within 96 hours.
Related Concept Videos
Antimicrobial Effectiveness
Acute Pyelonephritis II: Diagnostic Studies and Management
Drugs for Treatment of Ulcerative Colitis in IBD
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Antibiotic Selection
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

